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Objective: Melilotus ofﬁcinalis (L.) Pall. is commonly used for treating bronchitis, painful menstruation,
hemorrhoids, kidney stones, ulcers of the eyes, earache, and hardening and swelling of uterus. The
European Medicines Agency reported the use of M. ofﬁcinalis orally against stomach ache, gastric ulcer,
and disorders of the liver and uterus in folk medicine. The present study aimed to appraise the activity of
M. (L.) Pall. aerial parts in endometriosis rat model.
Materials and methods: The endometriosis rat model was used to evaluate the potential activity of
M. ofﬁcinalis aerial parts based on its folkloric usage. The aerial parts of M. ofﬁcinalis were extracted with
n-hexane, ethyl acetate (EtOAc), and methanol (MeOH), respectively. The adhesion scores, endometrial
foci areas, and cytokine levels were measured in all treated groups. After the biological activity studies,
phytochemical studies were performed on the active extract and the fractions obtained from the active
extract.
Results: The MeOH extract signiﬁcantly decreased the endometrial foci areas and cytokine levels in rats
with endometriosis. Fractionation was performed on the MeOH extract to achieve bioactive molecules.
Following the fractionation, the fractions obtained from the MeOH extract were tested. Fraction C
showed the highest activity in the rat endometriosis model. Phytochemical investigation of the active
fraction (Fraction C) resulted in isolation and elucidation of some quercetin and kaempferol glucoside
derivatives.
Conclusion: Fraction C obtained from the MeOH extract of M. ofﬁcinalis showed the highest activity,
yielding four glycosylated ﬂavonoids.
© 2020 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Melilotus ofﬁcinalis (L.) Pall. (Fabaceae) is native in Europe and
Asia and known as “yellow melilot, yellow sweet clover, and medicinal sweet clover” [1,2]. M. ofﬁcinalis is commonly used for
treating hemorrhoids, bronchitis, kidney stones, painful menstruation, earache, ulcers of the eyes, and hardening and swelling of
uterus [3,4]. The European Medicines Agency reported the traditional use of M. ofﬁcinalis orally against stomach ache, gastric ulcer,
and complaints of liver and uterus [5].

* Corresponding author. Department of Pharmacognosy, Faculty of Pharmacy,
Gazi University, Etiler, 06330, Ankara, Turkey. Fax: þ90 312 2235018.
E-mail address: esrak@gazi.edu.tr (E. Küpeli Akkol).

Biological activity studies demonstrated the antioxidant, antiinﬂammatory, and antiproliferative effects of M. ofﬁcinalis [6,7].
Some studies showed that this plant prevented skin aging, promoted tissue regeneration, and reduced fat deposition [8]. Previous
studies about phytochemical proﬁle of M. ofﬁcinalis reported that
M. ofﬁcinalis contains kaempferol, quercetin, and coumarin derivatives [3e5,9].
Endometriosis is deﬁned as the condition in which a tissue
resembling the uterine mucous membrane, or endometrium, if
found outside of the uterus. It can develop in the uterine ligaments,
ovaries, pelvic peritoneum, rectovaginal septum, covering the sigmoid colon, uterus, rectum, tubes or bladder, umbilicus, laparotomy
and episiotomy scars, tubal stumps, hernial sacs, appendix, cervix,
vagina, vulva or lymph glands [10]. The incidence of endometriosis
has increased in the last few decades. This increase is most probably

https://doi.org/10.1016/j.tjog.2020.01.008
1028-4559/© 2020 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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due to the growing use of laparoscopy in gynecologic practice,
making it easier to diagnose endometriosis. Endometriosis is
detected in 5%e15% of laparotomies and laparoscopies performed
on 30% of women with chronic pelvic pain and in up to 40% of
infertile women [11].
The present study describes the effects of extracts/fractions
obtained from the aerial parts of M. ofﬁcinalis in a surgicallyinduced endometriosis rat model by evaluating adhesion scores
of endometriotic implants, areas of endometriotic foci, and cytokine levels of the peritoneal ﬂuids of rats as well as the identiﬁcation of compounds in biologically active fractions.
Materials and methods
Plant material
M. ofﬁcinalis aerial parts were collected from Kızılcahamam,
Ankara in July 2013 and identiﬁed by Prof. Dr. Hayri Duman (Gazi
University, Department of Biology, Faculty of Science and Art,
Ankara). A voucher specimen has been kept in the Herbarium of
Faculty of Pharmacy, Gazi University, Ankara, Turkey (GUEF3420).
Preparation of the plant extracts
The aerial parts of M. ofﬁcinalis (400 g) were dried in the shade
and extracted successively with n-hexane, ethyl acetate (EtOAc)
and methanol (MeOH) for 48 h at room temperature (10  6L).
Solvents were removed under reduced pressure at 40  C to obtain
the extracts. The yields of the n-hexane, ethyl acetate, and methanol extracts were 5, 11, 18%, respectively.
Animals
Non-pregnant six-week-old female Wistar Albino rats (weighing 200e250 g) were purchased from Kobay Experimental Animals Laboratory, Ankara, Turkey. The rats were housed according
to the Guide for the Care and Use of Laboratory Animals. The
experimental procedure was approved by the Kobay Experimental
Animals Ethics Committee (Protocol number: 233). The rats were
kept in polysulfone cages at appropriate temperature and humidity. The environment where the rats were housed was under
light-controlled (12-h light/12-h dark) conditions at Kobay Animals Breeding and Experimental Research Center. All animals
received water and chow ad libitum during the experimental
period. The animals were quarantined for at least 2 weeks and the
estrous cycle was controlled with daily assessment of vaginal
cytology, and rats showing regular estrous cycles were used in this
model.

Fig. 1. Endometriotic implant view with adhesion. EI: Endometrial implant; B: Bowel.

abdomen were closed using USP 3/0 polyglactin suture (Lactasorb
PGLA®, Orhan Boz, Turkey). Another experiment was performed
under anesthesia 28 days after the ﬁrst operation (Fig. 1).
The areas of endometrial foci were calculated by measuring
their length, width, and height using a micrometer. The equation p/
6  length  width  height was used for calculating endometriotic
volumes [13e15]. Furthermore, intra-abdominal adhesions were
scored according to the Blauer's scoring system as follows: 0, no
adhesion; 1, thin adhesions; 2, thick adhesions in one area; 3,
widespread thick adhesions; and 4, adhesions of the internal organs to the abdominal wall [16]. After the all experiments, the
abdomen was closed.

The administration of the extracts and fractions
Thirty rats were divided into ﬁve groups, with six rats in each
group to evaluate the activity of extracts whereas thirty-six rats
were randomly divided into six groups to evaluate the activity of
fractions. After the second experiment, 0.5% carboxymethylcellulose (CMC) (control group), extracts of different polarity and fractions were administered orally once a day for 4 weeks. The
reference group received buserelin acetate (20 mg/rat, subcutaneously) once per week. The extracts and fractions were applied to
the rats at the dose of 100 mg/kg.
After giving test materials to the rats, all rats were sacriﬁced. The
areas of endometriotic foci, intra-abdominal adhesions, and cytokine levels of the peritoneal ﬂuids were again calculated and
compared with those of the control group.

Induction of endometriosis
The endometriosis rat model was performed according to the
Vernon and Wilson method with some modiﬁcations [12]. All the
rats were anesthetized with intramuscular administration of the
combination of 1 mL ketamine (50 mg/mL) and 1 mL xylazine
(20 mg/mL). After anesthesia, the rats were placed in supine position and routine antisepsis was conducted for disinfection. A 3-cm
incision was made using a scalpel. The subcutaneous and muscle
layers were separated, and the abdominal cavity was opened. The
right uterine horn was removed, and a 1.5-cm piece of the tissue
was trimmed using microscissors. The trimmed segment was put in
0.9% sodium chloride (normal saline) and longitudinally opened.
The removed endometrial tissue fragment was sutured into the
abdominal wall of the same rat using USP 4/0 polyglactin suture
(Lactasorb PGLA®, Orhan Boz, Turkey). The muscle layers of the

Techniques for histopathological investigation
Firstly, all endometrium tissues from the normal and experimental groups were ﬁxed with 10% formaldehyde. All tissues were
detected using the Thermo Scientiﬁc Excelsior (ES) machine. The
tissues were embedded in parafﬁn wax and blocks were prepared
using the HistoCentre 2 machine. Subsequently, sections of 3.5 mm
thickness were made from parafﬁn-embedded blocks using a Leica
RM2255 microtome. The sections were stained with
hematoxylineeosin (HE) using the Shandon Varistan machine.
Photographs of normal and pathological endometrium tissues were
taken using Nikon Eclipse Ci with both polarizing attachment and
Digital Image analysis system, which were then examined under a
light microscope.
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Measuring of cytokine levels

Isolation procedure for the MeOH extract

The peritoneal ﬂuid was collected to detect the tumor necrosis
factor (TNF)-a, vascular endothelial growth factor (VEGF), and
interleukin (IL)-6 levels in rats. TNF-a, VEGF (Cusabio, USA; catalog
numbers CSB-E11987r and CSB-E04757r), and IL-6 (Bio Source International, Nivelles, Belgium; catalog number MBS701221) levels
were quantitatively evaluated using the commercially available
enzyme-linked immunosorbent assay kits according to the manufacturer's protocol. After the scariﬁcation of animals, the peritoneal
ﬂuid was again collected, and the aforementioned process was
performed. The pre- and post-treatment results were assessed.

The MeOH extract of the plant was subjected to silica gel column
to obtain 41 fractions. The fractions were pooled to get four subfractions (A-D) after thin-layer chromatography analysis using
CHCl3:MeOH
(9:1),
CHCl3:MeOH:H2O
(8:2:0.25),
and
EtOAc:CHCl3:MeOH:H2O (6:4:4:1) as the mobile phases. The active
Fractions B and C were subjected to column chromatography over
Sephadex LH-20 and RP-18 silica to obtain pure compounds. The
structural elucidation of the compounds was achieved by their
nuclear magnetic resonance and mass data analyses (Fig. 2).
Results

Statistical analysis
Biological activity results
The results were expressed as mean ± standard error of the
mean (S.E.M.). The ANOVA-Dunnett's test was performed to
determine the signiﬁcant differences among groups using GraphPad Prism 6.0. p values less than 0.05 were considered signiﬁcant.

The present study investigated the effects of extracts obtained
from the aerial parts of M. ofﬁcinalis in a surgically-induced endometriosis rat model by evaluating adhesion scores of endometriotic

Fig. 2. Isolated compounds from active fractions of the MeOH extract of M. ofﬁcinalis.
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The application of MeOH extract signiﬁcantly decreased TNF-a,
VEGF, and IL-6 levels to 5.2, 17.4, and 42.5 pg/mL, respectively.
Although the application of n-hexane and EtOAc extract decreased
the cytokine levels, no statistical difference was noted compared
with the control group (Table 3).
In addition to the MeOH extract, the reference group (buserelin
acetate) also signiﬁcantly reduced the adhesion scores, endometriotic implant volumes, and cytokine levels of the peritoneal ﬂuids.
After the MeOH extract was found to display the remarkable
activity in the rat endometriosis model, it was fractionated using a
silica column to obtain four main fractions (Frs. A-D). The activities
of the four main fractions were also tested in the rat endometriosis
model. Among the fractions obtained from the MeOH extract,
Fractions B and C signiﬁcantly decreased adhesion scores to 1.9 and
0.9, respectively (Table 1). Furthermore, the endometriotic implant
volumes decreased to 64.9 and 48.3 mm3 in groups treated with
Fractions B and C, respectively (Table 2). Fraction C also signiﬁcantly
decreased TNF-a, VEGF, and IL-6 levels of the peritoneal ﬂuids,
whereas Fraction B signiﬁcantly decreased the only IL-6 level of the
peritoneal ﬂuids (Table 3).
Quercetin-3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyranoside
(1), kaempferol 3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyranoside (2), kaempferol 3-O-a-L-rhamnopyranosyl-(1/6)-b-D-galactopyranosyl-7-O-a-L-rhamnopyranoside (3), and kaempferol 3O-a-L-rhamnopyranosyl-(1/2)-[a-L-rhamnopyranosyl-(1/6)]-bD-galactopyranosyl-7-O-a-L-rhamnopyranoside (4) were isolated
and identiﬁed from Fraction C, which showed higher activity
compared to those of other three fractions. In addition to Fraction C,
Fraction B also signiﬁcantly decreased adhesion scores and endometriotic implant volumes. Uridine (5), methyl-a-D-fructofuranoside (6), and melilofﬁcinaside (7) were isolated and identiﬁed from
Fraction B.
According to histopathological analyses, whereas a number of
endometrial glands (G) and mononuclear cell inﬁltration (MCI)
were observed in the control groups, the decrease in G and MCI was
detected in the reference, MeOH extract, Frs. B and C treated
groups. The severity of the lesions was reduced in the n-hexane,
EtOAc, MeOH, and reference groups, respectively (Fig. 3). Histopathological ﬁndings showed that the severity of the lesions was
reduced in the Fr D, Fr. A, Fr. B, Fr. C, and reference groups,
respectively (Fig. 4).

Table 1
Intraabdominal adhesion scores of the endometriotic implants of extracts and
fractions from MeOH extract prepared from Melilotus ofﬁcinalis.
Groups

Adhesion scores
Pre-treatment

Post-treatment

Control
n-Hexane extract
EtOAc extract
MeOH extract
Reference

3.1
3.3
3.2
2.9
3.6

±
±
±
±
±

1.1
0.9
0.7
1.1
0.5

3.7 ± 1.0
2.6 ± 0.8
2.2 ± 0.7
1.8 ± 1.1
0.0 ± 0.0***

Control
Fr. A
Fr. B
Fr. C
Fr. D
Reference

3.4
3.6
3.1
3.1
2.7
3.5

±
±
±
±
±
±

0.8
0.3
0.5
0.6
1.0
0.7

3.8 ± 0.5
2.4 ± 1.3
1.9 ± 0.9*
0.9 ± 0.1**
2.6 ± 0.7
0.0 ± 0.0***

*: p < 0.05; **: p < 0.01; ***: p < 0.001; S.E.M.: Standard Error of Mean.

Table 2
Comparison of the pre-treatment and the post-treatment endometriotic implant
volumes.
Material

Volume of Endometrioma (mm3) ± S.E.M.

Control
n-Hexane extract
EtOAc extract
MeOH extract
Reference

98.4
94.5
86.1
81.9
96.2

±
±
±
±
±

10.7
9.6
12.3
9.9
8.7

112.3 ± 14.2
86.9 ± 8.2
71.8 ± 9.9
54.4 ± 7.2**
23.5 ± 3.8***

Control
Fr. A
Fr. B
Fr. C
Fr. D
Reference

99.1
98.3
92.6
96.2
86.3
96.8

±
±
±
±
±
±

10.3
9.9
12.4
11.9
8.5
9.6

105.3 ± 9.4
85.1 ± 8.4
64.9 ± 9.1*
48.3 ± 6.1***
85.7 ± 9.1
25.3 ± 4.2***

Pre-treatment

Post-treatment

**: p < 0.01; ***: p < 0.001; S.E.M.: Standard Error of Mean.

implants, areas of endometriotic foci, and cytokine levels of the
peritoneal ﬂuids of rats. Statistically signiﬁcant difference was not
found in adhesion scores among the extract-treated groups
compared with the control group (Table 1).
Taking into consideration endometriotic implant volumes, the
application of the MeOH extract signiﬁcantly decreased endometriotic implant volumes from 81.9 to 54.4 mm3. Nevertheless, no
statistically signiﬁcant difference was observed between groups
treated with other extracts and the control group (Table 2).
In addition to adhesion scores and endometriotic implant volumes, the cytokine levels of the peritoneal ﬂuids were examined.

NMR data of isolated compounds
Quercetin-3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyranoside (1) d 1H-NMR (400 MHz, DMSO): d 7.71 (1H, dd, J ¼ 8.4, 2.1 Hz,
H-60 ), 7.59 (1H, d, J ¼ 2.1 Hz, H-20 ), 6.84 (1H, d, J ¼ 8.4 Hz, H-50 ), 6.79

Table 3
Peritoneal TNF-a, VEGF and IL-6 levels before and after treatment in all groups.
Material

Peritoneal TNF-a level (pg/ml)

Peritoneal VEGF level (pg/ml)

Peritoneal IL-6 level (pg/ml)

Pre-treatment

Post-treatment

Pre-treatment

Post-treatment

Pre-treatment

Control
n-Hexane extract
EtOAc extract
MeOH extract
Reference

12.6 ± 4.5
9.3 ± 2.7
11.2 ± 3.8
10.1 ± 2.5
11.3 ± 3.4

9.3 ± 3.8
8.5 ± 2.4
8.4 ± 2.5
5.2 ± 0.9*
1.9 ± 0.4***

24.6
22.5
26.7
28.1
21.5

±
±
±
±
±

5.9
7.1
9.3
8.2
8.4

26.2 ± 6.3
19.2 ± 7.2
19.7 ± 11.0
17.4 ± 4.3*
9.6 ± 2.3***

52.2
51.4
56.3
53.5
51.2

±
±
±
±
±

9.3
11.4
10.9
15.8
10.8

54.7 ± 12.1
46.2 ± 11.4
47.8 ± 9.3
42.5 ± 8.1*
24.3 ± 7.4***

Control
Fr. A
Fr. B
Fr. C
Fr. D
Reference

16.1
17.8
14.3
15.3
18.3
17.2

13.4 ± 6.6
16.3 ± 8.1
13.6 ± 6.9
3.5 ± 0.9**
19.6 ± 8.8
1.2 ± 0.8***

31.4
24.7
22.5
26.4
29.4
27.1

±
±
±
±
±
±

9.4
5.9
10.5
7.5
9.6
7.0

28.7 ± 8.3
24.5 ± 9.1
19.8 ± 8.6
12.3 ± 4.6**
22.5 ± 6.2
8.8 ± 1.1***

56.4
59.3
54.1
56.6
52.5
55.3

±
±
±
±
±
±

10.4
10.1
7.3
11.4
13.7
9.0

59.1 ± 11.8
55.1 ± 13.6
45.6 ± 8.3*
33.9 ± 6.3**
49.6 ± 11.1
22.5 ± 6.4***

±
±
±
±
±
±

4.7
9.5
8.9
8.2
7.6
6.1

*: p < 0.05; **: p < 0.01; ***: p < 0.001; S.E.M.: Standard Error of Mean.

Post-treatment
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Fig. 3. Histopathological views of all extracts-treated groups. (A): Control group, Original magniﬁcation was 10, HE (B): n-Hexane extract-treated group, Original magniﬁcation
was 10, HE (C): EtOAc extract-treated group, Original magniﬁcation was 40, HE (D): MeOH extract-treated group, Original magniﬁcation was 40, HE (E): Reference group,
Original magniﬁcation was 40, HE Arrow pointed abbreviation: G: Endometrial gland; F: Fibroblast; MCI: Mononuclear cell inﬁltration; C: Collagen; E: Endometrial gland
epithelium; BV: Blood Vessel; DG: Degenerative endometrial glands; DC: Degenerative collagen ﬁbers.

(1H, d, J ¼ 2.1 Hz, H-8), 6.44 (1H, d, J ¼ 2.1 Hz, H-6), 5.55 (1H, d,
J ¼ 2.0 Hz, H-1000 ), 5.41 (1H, d, J ¼ 7.7 Hz, H-100 ), 3.85e3.02 (the
protons of sugars), 1.13 (3H, d, J ¼ 6.1 Hz, H-6000 ); 13C-NMR
(100 MHz, DMSO) d 177.7 (C-4), 161.6 (C-7), 160.9 (C-5), 156.8 (C-2),
155.9 (C-9), 148.7 (C-40 ), 144.9 (C-30 ), 133.8 (C-3), 122.1 (C-60 ), 121.0
(C-10 ), 116.1 (C-20 ), 115.3 (C-50 ), 105.6 (C-10), 101.7 (C-100 ), 99.4 (C-6),
98.5 (C-1000 ), 94.4 (C-8), 75.9 (C-500 ), 73.2 (C-300 ), 71.7 (C-200 ), 71.2 (C4000 ), 70.3 (C-5000 ), 70.1 (C-3000 ), 69.9 (C-400 ), 68.0 (C-2000 ), 60.2 (C-600 ),
18.0 (C-6000 ). HRESIMS: m/z ¼ 611.1606 [MþH]þ (calcd. 611.1612 for
C27H31O16).

Kaempferol
3-O-b-D-glucopyranosyl-7-O-a-L-rhamnopyranoside (2) d 1H-NMR (500 MHz, CD3OD): d 8.11 (2H, d, J ¼ 8.7 Hz,
H-20 , 60 ), 6.89 (2H, d, J ¼ 8.7 Hz, H-30 , 50 ), 6.75 (1H, d, J ¼ 2.1 Hz, H-8),
6.46 (1H, d, J ¼ 2.1 Hz, H-6), 5.57 (1H, d, J ¼ 1.8 Hz, H-1000 ), 5.20 (1H,
d, J ¼ 7.7 Hz, H-100 ), 4.02e3.45 (the protons of sugars), 1.25 (3H, d,
J ¼ 6.2 Hz, H-6000 ); 13C-NMR (125 MHz, CD3OD) d 179.8 (C-4), 163.6
(C-7), 162.8 (C-5), 161.8 (C-40 ), 159.6 (C-2), 158.0 (C-9), 135.7 (C-3),
132.5 (C-20 , 60 ), 122.5 (C-10 ), 116.2 (C-30 , 50 ), 107.3 (C-10), 104.6 (C100 ), 100.6 (C-6), 99.8 (C-1000 ), 95.6 (C-8), 77.2 (C-500 ), 74.9 (C-300 ), 73.6
(C-200 ), 73.0 (C-4000 ), 72.0 (C-400 ), 71.7 (C-3000 ), 71.3 (C-2000 ), 70.0 (C-5000 ),
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Fig. 4. Histopathological views of all fractions-treated groups. (A): Control group, Original magniﬁcation was 10, HE (B): Fraction A-treated group, Original magniﬁcation was 40,
HE (C): Fraction B-treated group, Original magniﬁcation was 40, HE (D): Fraction C-treated group, Original magniﬁcation was 4, HE (E): Fraction D-treated group, Original
magniﬁcation was 10, HE (F): Reference group, Original magniﬁcation was 40, HE Arrow pointed abbreviation: G: Endometrial gland; F: Fibroblast; MCI: Mononuclear cell
inﬁltration; C: Collagen; E: Endometrial gland epithelium; BV: Blood Vessel; DG: Degenerative endometrial glands; DC: Degenerative collagen ﬁbers; S: Stroma.

62.0 (C-600 ), 18.1 (C-6000 ). HRESIMS: m/z ¼ 595.1657 [MþH]þ (calcd.
595.1663 for C27H31O15).
Kaempferol
3-O-a-L-rhamnopyranosyl-(1/6)-b-D-galactopyranosyl-7-O-a-L-rhamnopyranoside (3) d 1H-NMR
(400 MHz, DMSO): d 8.10 (2H, d, J ¼ 8.8 Hz, H-20 , 60 ), 6.88 (2H, d,
J ¼ 8.8 Hz, H-30 , 50 ), 6.81 (1H, d, J ¼ 2.2 Hz, H-8), 6.45 (1H, d,
J ¼ 2.2 Hz, H-6), 5.56 (1H, d, J ¼ 1.8 Hz, H-1000 '), 5.36 (1H, d, J ¼ 7.7 Hz,
H-100 ), 4.41 (1H, d, J ¼ 1.6 Hz, H-1000 ), 3.86e3.09 (the protons of
sugars), 1.13 (3H, d, J ¼ 6.1 Hz, H-6000 '), 1.07 (3H, d, J ¼ 6.1 Hz, H-6000 );
13
C-NMR (100 MHz, DMSO) d 177.7 (C-4), 161.7 (C-7), 160.8 (C-5),
160.3 (C-40 ), 157.1 (C-2), 156.1 (C-9), 133.6 (C-3), 131.1 (C-20 , 60 ),

120.7 (C-10 ), 115.2 (C-30 , 50 ), 105.6 (C-10), 99.4 (C-6), 94.7 (C-8), 7rha: 98.5 (C-1), 71.7 (C-4), 70.3 (C-3), 70.1 (C-2), 69.9 (C-5), 17.8
(C-6), 3-gal: 101.9 (C-1), 73.7 (C-5), 73.0 (C-3), 71.1 (C-2), 68.3 (C-4),
65.3 (C-6), Rha (C-6 of gal): 100.1 (C-1), 72.0 (C-4), 70.6 (C-3), 70.4
(C-2), 68.0 (C-5), 17.9 (C-6). HRESIMS: m/z ¼ 741.2229 [MþH]þ
(calcd. 741.2242 for C33H41O19).
Kaempferol 3-O-a-L-rhamnopyranosyl-(1/2)-[a-L-rhamnopyranosyl-(1/6)]-b-D-galactopyranosyl-7-O-a-L-rhamnopyranoside (4) d 1H-NMR (500 MHz, CD3OD): d 8.09 (2H, d, J ¼ 8.9 Hz,
H-20 , 60 ), 6.87 (2H, d, J ¼ 8.9 Hz, H-30 , 50 ), 6.73 (1H, d, J ¼ 2.2 Hz, H-8),
6.46 (1H, d, J ¼ 2.2 Hz, H-6), 5.60 (1H, d, J ¼ 7.7 Hz, H-100 ), 5.56 (1H,
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d, J ¼ 1.7 Hz, H-1000 ''), 5.23 (1H, d, J ¼ 1.6 Hz, H-1000 '), 4.52 (1H, d,
J ¼ 1.6 Hz, H-1000 ), 4.01e3.27 (the protons of sugars), 1.26 (3H, d,
J ¼ 6.1 Hz, H-6000 '), 1.17 (3H, d, J ¼ 6.3 Hz, H-6000 ''), 0.99 (3H, d,
J ¼ 6.3 Hz, H-6000 ); 13C-NMR (125 MHz, CD3OD) d 179.5 (C-4), 163.3
(C-7), 162.9 (C-5), 162.9 (C-40 ), 159.5 (C-2), 157.9 (C-9), 134.5 (C-3),
132.4 (C-20 , 60 ), 121.7 (C-10 ), 116.9 (C-30 , 50 ), 107.4 (C-10), 100.4 (C-6),
95.6 (C-8), 7-rha: 99.9 (C-1), 73.6 (C-4), 72.1 (C-3), 71.7 (C-2), 71.2
(C-5), 18.1 (C-6), 3-gal: 100.8 (C-1), 77.5 (C-2), 75.8 (C-3), 75.4 (C-5),
70.7 (C-4), 67.1 (C-6), Rha (C-6 of gal): 101.8 (C-1), 73.9 (C-4), 72.2
(C-3), 72.1 (C-2), 69.7 (C-5), 17.9 (C-6), Rha (C-2 of gal): 102.6 (C-1),
74.0 (C-4), 72.4 (C-2), 72.3 (C-3), 69.9 (C-5), 17.6 (C-6). HRESIMS: m/
z ¼ 887.2826 [MþH]þ (calcd. 887.2821 for C39H51O23).
Uridine (5) d 1H-NMR (400 MHz, CD3OD): d 8.01 (1H, d,
J ¼ 8.0 Hz, H-6), 5.90 (1H, d, J ¼ 4.7 Hz, H-10 ), 5.70 (1H, d, J ¼ 8.0 Hz,
H-5), 4.18 (1H, t, J ¼ 4.7 Hz, H-20 ), 4.15 (1H, t, J ¼ 4.7 Hz, H-30 ), 4.01
(1H, m, H-40 ), 3.84 (1H, dd, J ¼ 12.2, 2.7 Hz, H-50 b), 3.73 (1H, dd,
J ¼ 12.2, 3.2 Hz, H-50 a); 13C-NMR (100 MHz, CD3OD) d 166.2 (C-4),
152.5 (C-2), 142.8 (C-6), 102.7 (C-5), 90.8 (C-10 ), 86.4 (C-40 ), 75.8 (C20 ), 71.4 (C-30 ), 62.3 (C-60 ). HRESIMS: m/z ¼ 451.1613 [MþH]þ (calcd.
451.1604 for C9H13N2O6).
Methyl-a-D-fructofuranoside (6) d 1H-NMR (400 MHz,
CD3OD): d 4.05 (1H, d, J ¼ 4.1 Hz, H-3), 3.92 (1H, m, H-4), 3.87 (1H,
m, H-5), 3.78 (1H, dd, J ¼ 12.0, 1.8 Hz, H-6b), 3.74 (1H, dd, J ¼ 12.0,
5.1 Hz, H-6a), 3.66 (1H, d, J ¼ 11.9 Hz, H-1b), 3.65 (1H, d, J ¼ 11.9 Hz,
H-1a), 3.33 (3H, s, OCH3); 13C-NMR (100 MHz, CD3OD) d 109.2 (C-2),
84.6 (C-5), 82.6 (C-3), 78.9 (C-4), 62.8 (C-6), 60.5 (C-1), 48.9 (OCH3).
HRESIMS: m/z ¼ 195.0859 [MþH]þ (calcd. 195.0868 for C7H15O6).
Melilofﬁcinaside (7) d 1H-NMR (500 MHz, pyridine): d 7.55
(1H, dd, J ¼ 8.3 Hz, 1.9 Hz, H-5), 7.21 (1H, d, J ¼ 8.1 Hz, H-60 ), 7.11
(1H, dd, J ¼ 8.3 Hz, 2.3 Hz, H-6), 7.09 (1H, d, J ¼ 2.3 Hz, H-8), 6.71
(1H, d, J ¼ 2.3 Hz, H-30 ), 6.59 (1H, dd, J ¼ 8.1 Hz, 2.3 Hz, H-50 ), 5.67
(1H, d, J ¼ 7.2 Hz, H-100 ), 5.58 (1H, dd, J ¼ 7.8 Hz, 1.9 Hz, H-4), 4.28
(1H, m, H-2), 3.72 (1H, m, H-2), 3.67 (3H, s, OCH3), 3.57 (1H, m, H3); 13C-NMR (125 MHz, pyridine) d 162.0 (C-40 ), 161.7 (C-20 ), 160.2
(C-7), 157.5 (C-9), 132.9 (C-5), 125.8 (C-60 ), 120.2 (C-10 ), 115.1 (C-10),
111.5 (C-6), 107.0 (C-50 ), 105.6 (C-8), 97.6 (C-30 ), 79.2 (H-4), 67.2 (C2), 55.8 (C-40 -OCH3), 40.4 (C-3); sugar moiety: 102.4 (C-100 ), 79.3 (C300 ), 78.8 (C-500 ), 75.2 (C-200 ), 71.5 (C-400 ), 62.6 (C-600 ). HRESIMS: m/
z ¼ 451.1613 [MþH]þ (calcd. 451.1604 for C22H27O10).
Discussion
M. ofﬁcinalis is commonly used for the treating ulcers of the
eyes, earache, bronchitis, hemorrhoids, kidney stones, and painful
menstruation, swelling and hardening of uterus [3,4]. The European
Medicines Agency reported the use of M. ofﬁcinalis orally against
stomach ache, gastric ulcer, and disorders of liver and uterus in folk
medicine [5].
Previous studies reported that M. ofﬁcinalis has some biological
activities such as the antioxidant, antiproliferative and antiinﬂammatory effects [6,7]. Pastorino et al. also showed that
M. ofﬁcinalis promoted tissue regeneration, prevented skin aging,
and reduced fat deposition [8].
Endometriosis is a disease deﬁned by the availability and
growth of endometrial tissue outside the uterus, especially into the
peritoneum.
Some
biological
changes,
such
as
local
inﬂammatoryereparative phenomena and involvement of peripheral blood mononuclear cells, are observed in the peritoneal ﬂuid of
women with endometriosis [17]. Pizzo et al. (2002) reported that
the peritoneal ﬂuid levels of TNF-a were extremely high in early
stage [18]. The other study demonstrated that the levels of cytokines including VEGF, IL-6, IL-1b and TNF-a were higher in women
with endometriosis, indicating their role in the pathogenesis of
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endometriosis [19]. However, no signiﬁcant difference was
observed in the serum levels of IL-5, IL-7, and IL-12 between
women with endometriosis and healthy women [20]. Koyama et al.
(1993) found that the levels of IL-5 and IL-6, but not IL-1, were
related to endometriosis [21]. Li et al. (2017) showed that disorders
involving IL-6 and IL-6 receptors were correlated with the etiology
of endometriosis. An increase in the IL-6 soluble receptor in the
peritoneal ﬂuid promoted the development of endometriosis by
enhancing the bioactivity of IL-6 [22]. In the light of these informations, the cytokine levels in the peritoneal ﬂuids were evaluated in the present study. According to the results, the cytokine
levels decreased in the MeOH extractetreated and reference
groups.
Sex steroids such as progesterone and estrogen are essentially
produced in the ovaries and these type hormones cause the growth
of endometrial tissue, basically by stimulating and inhibiting cell
proliferation. Furthermore, estrogen plays a signiﬁcant role in the
regulation of cyclic gonadotropin release and in folliculogenesis
[23]. Collins-Burow et al. (2000) reported that some ﬂavonoids
possess antiestrogenic activity as well as estrogenic activity. The
antiestrogenic activities of ﬂavonoids such as apigenin, luteolin,
kaempferide are more than their estrogenic activities [24].
Furthermore, ﬂavonoids decrease the expression and secretion of
cytokines [25]. Another study showed that apigenin inhibited TNFa-induced cell proliferation and reduced the mitogenic activity and
inﬂammatory response in endometriotic stromal cells [26]. Apigenin was similarly stated to inhibit the proliferation and tumorigenesis of human ovarian cancer A2780 cells in vitro and might
serve as a substitute compound for treating endometrial cancer in
postmenopausal women [27].
Endometriotic lesions are qualiﬁed by a deep vascularization
that occurs through angiogenesis process [28e31]. VEGF which is
one of the most potent angiogenic factors is postulated to be
involved in the progress of the ectopic lesions in endometriosis
[32,33]. Vascularization and VEGF and its receptor expression are
mainly high in deeply inﬁltrating endometriosis. Those situations
supported that the antiangiogenic therapy contribute to the
regression of endometriosis. Kim (2003) searched the antiangiogenic potential of ﬂavonoids. Their results reported that the
ﬂavonoids displayed antiangiogenic effect preventing VEGF/basic
ﬁbroblast growth factor-induced matrix metalloproteinase (MMP)1 and the activation of pro-MMP-2 [34]. Another study conducted
by Wu et al. (2012) showed that the ﬂavonoid extract including
some quercetin and kaempferol derivatives were active in inhibiting expression of intercellular adhesion molecule-1 and vascular
cell adhesion molecule induced by TNF-a in human umbilical vein
endothelial cells [35]. Previous studies reported that quercetin
showed antiangiogenic effect by decreasing the phosphorylation
and mRNA expression of VEGF receptor (VEGFR)-2, the expression
of cyclooxygenase (COX)-2 and the secretion of MMP-2 and MMP-9
[36e40]. Kaempferol also displayed antiangiogenic effect by
reducing VEGF secretion, VEGF mRNA and protein expression,
MMP-2 and MMP-9 activity [41e43]. Another studies which is
about the antiangiogenic effects of ﬂavonoids exhibited that apigenin inhibited Smad2/3 and Src/FAK/AKT pathways, IL-6/STAT3
pathway, mRNA and protein expression of IL-6, IL-8 and
decreased MMP-2 and -9 activities [44e46].
In the present study, Fraction C obtained from the MeOH extract
showed the highest activity in the rat endometriosis model, and four
glycosylated ﬂavonoids were isolated from this fraction. Based on
the ﬁndings of previous studies and the present study, it was suggested that the MeOH extract of the aerial parts of M. ofﬁcinalis could
be used to treat endometriosis due to its glycosylated ﬂavonoids.
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Conclusions
This novel study described the role of M. ofﬁcinalis against
endometriosis. The present study proved the traditional use of the
aerial parts of M. ofﬁcinalis in endometriosis. Four ﬂavonoid glycosides (1e4) were isolated as the main components of the active
fraction, which might be responsible for the activity of plant extract
in the endometriosis rat model. In addition, compounds 5e7 were
isolated from Fraction B which showed moderate activity. Therefore, the effect of the extract could be attributed to glycosylated
ﬂavonoids. Furthermore, the authors think that the action mechanism of glycosylated ﬂavonoids is due to their antiangiogenic
properties. In further studies, we are planning to conduct the doseeffect studies in the rat endometriosis model.
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